Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer.
Zoulikha RezougStephanie P TottenDavid SzlachtyczAdrienne AtayanKristen MohlerSophie AlbertLeila FengBrianna Lemieux AnglinZhen ShenDaniel JimenezNancy HamelNicholas MetiKhashayar EsfahaniJean-François BoileauIpshita PrakashMark BasikSarkis MeterissianFrancine TremblayDavid FleiszerDawn AndersonGeorge ChongStephanie M WongWilliam D FoulkesPublished in: JAMA network open (2024)
In this cross-sectional universal genetic testing study of women with newly diagnosed invasive breast cancer, the prevalence of GPVs was 7.3%, with 5.3% of patients testing positive for B1B2P2. Among B1B2P2-women women, one-third were eligible for PARP inhibitors.